Alternatively, the prognostic impact of blood parameters accounting for systemic and intratumor inflammation/immunity might be more strongly associated with the prognosis of HER2+ BC patients with advanced disease, which is typically characterized by more severe alterations in the number or activation status of specific immune cell populations [41]. The gene discussed is ERBB2; the disease is breast cancer.